These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 24637685

  • 1. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
    Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A.
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3091-9. PubMed ID: 24637685
    [Abstract] [Full Text] [Related]

  • 2. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
    Fernández-Esgueva M, López-Calleja AI, Mulet X, Fraile-Ribot PA, Cabot G, Huarte R, Rezusta A, Oliver A.
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
    [Abstract] [Full Text] [Related]

  • 3. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA, Cabot G, Mulet X, Periañez L, Martín-Pena ML, Juan C, Pérez JL, Oliver A.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):658-663. PubMed ID: 29149337
    [Abstract] [Full Text] [Related]

  • 5. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
    Zamorano L, Reeve TM, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.
    Antimicrob Agents Chemother; 2011 May 01; 55(5):1990-6. PubMed ID: 21357303
    [Abstract] [Full Text] [Related]

  • 6. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM.
    Int J Antimicrob Agents; 2019 Jun 01; 53(6):774-780. PubMed ID: 30831233
    [Abstract] [Full Text] [Related]

  • 7. In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
    Goodlet KJ, Nicolau DP, Nailor MD.
    Antimicrob Agents Chemother; 2017 Dec 01; 61(12):. PubMed ID: 28923865
    [Abstract] [Full Text] [Related]

  • 8. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
    Castanheira M, Mills JC, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2014 Nov 01; 58(11):6844-50. PubMed ID: 25182652
    [Abstract] [Full Text] [Related]

  • 9. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
    Berrazeg M, Jeannot K, Ntsogo Enguéné VY, Broutin I, Loeffert S, Fournier D, Plésiat P.
    Antimicrob Agents Chemother; 2015 Oct 01; 59(10):6248-55. PubMed ID: 26248364
    [Abstract] [Full Text] [Related]

  • 10. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A.
    Antimicrob Agents Chemother; 2017 Nov 01; 61(11):. PubMed ID: 28874376
    [Abstract] [Full Text] [Related]

  • 11. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
    Gomis-Font MA, Cabot G, López-Argüello S, Zamorano L, Juan C, Moyá B, Oliver A.
    J Antimicrob Chemother; 2022 Mar 31; 77(4):957-968. PubMed ID: 35084040
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM, Chen HY.
    J Antimicrob Chemother; 1997 Sep 31; 40(3):335-43. PubMed ID: 9338484
    [Abstract] [Full Text] [Related]

  • 13. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling.
    Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM.
    Antimicrob Agents Chemother; 2023 Oct 18; 67(10):e0048023. PubMed ID: 37695298
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam.
    Huang W, Hamouche JE, Wang G, Smith M, Yin C, Dhand A, Dimitrova N, Fallon JT.
    Int J Mol Sci; 2020 Feb 04; 21(3):. PubMed ID: 32033143
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G.
    Antimicrob Agents Chemother; 2022 Feb 15; 66(2):e0206721. PubMed ID: 34930034
    [Abstract] [Full Text] [Related]

  • 19. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD, Taracila MA, Rutter JD, Bethel CR, Galdadas I, Hujer AM, Caselli E, Prati F, Dekker JP, Papp-Wallace KM, Haider S, Bonomo RA.
    mBio; 2018 Dec 11; 9(6):. PubMed ID: 30538183
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.